Major Depressive Disorder

The results show depressive disorders in the first cohort were associated with a nearly 4-fold higher risk of depressive disorders in the spousal cohort.

State adoption of both SNAP eligibility policies, where the state eliminates the asset test and increases the income limit resulted in decreases in the rates of past-year major depressive episodes, mental illness, serious mental illness, and suicidal ideation.

Electroconvulsive therapy was superior to ketamine in a sensitivity analysis of methodologically stronger trials and also was better in study-defined response and remission for patients with major depressive episodes.

There was also significantly greater reductions in anxiety, Afghan-cultural distress symptoms, and psychiatric difficulties compared to the treatment as usual group.

There was a lower probability of initiating psycholeptics and having postpartum psychiatric emergencies in the early discontinuer and late discontinuer groups compared to the continuers.

Zuranolone is being evaluated as a 14 day, rapid-acting, once-daily, oral treatment for adult patients with MDD and PPD. The drug is an oral neuroactive steroid GABA-A receptor positive allosteric modulator.

The results show 28.9% of the aripiprazole augmentation group achieved remission, compared to 28.2% of the bupropion augmentation group and 19.3% of the bupropion switch group.

The results from a Bayesian reinforcement learning model showed the antidepressant placebo trial-wise expectancies were updated by composite learning signals multiplexing sensory evidence and trial-wise mood.

According to the data, sleep quality, fatigue, and social well-being contribute to depression among young adults with autism, with social well-being being a significant predictor of depression over a 2-year period.

Exposure to maternal, paternal, or full sibling major depression was associated with a two-fold higher risk of major depression for men.

Andrew J Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, comment on the need to improve awareness around depressive disorders and break the stigma of mental health treatment.

Experts in psychiatry review emerging mechanisms of action in the treatment landscape of MDD.

An international review of data show certain antidepressants may benefit conditions like fibromyalgia, but many trials are actually inconclusive.

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, share their approach to treatment-resistant depression.

Drs Andrew J. Cutler, Gregory Mattingly, and Sagar V. Parikh discuss the treatment of MDD in female patients who are pregnant or plan to become pregnant.

The same risk was not found for offspring of fathers with primary immunodeficiencies.

Experts in psychiatry review factors to consider when deciding to switch or augment treatment in major depressive disorder [MDD].

Drs Andrew J Cutler, Gregory Mattingly, and Sagar V Parikh provide advice to clinicians on monitoring treatment in major depressive disorder.

Experts in psychiatry provide insight into treating episodic vs chronic major depressive disorder and factors they consider when approaching treatment selection.

Andrew J Cutler, MD; Gregory Mattingly, MD; and Sagar V Parikh, MD, FRCPC, discuss clinical data on zuranolone from the WATERFALL, CORAL, and SHORELINE studies for the treatment of major depressive disorder.

Personality disorders, adjustment disorder, bipolar disorder, insomnia, and anxiety disorders were risk factors associated with postpartum depression.

Use of Zuranolone for Treatment of MDD

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, review newly approved additions to the major depressive disorder treatment landscape, including esketamine, brexanolone, AXS-05 (dextromethorphan/bupropion).

Experts in psychiatry discuss unmet needs in the treatment of major depressive disorder and how new agents are aiming to fulfill these needs.

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, comment on the limitations and challenges of traditional treatments for MDD, such as length of treatment and adverse events.

Patients with late-onset depression died on average 1 year earlier than those with early-onset depression or those without late-life depression.

A new cross-sectional analysis suggest there are few options available for patients with schizophrenia or a serious mood disorder.

Sagar V. Parikh, MD, FRCPC, reviews factors that lead to the use of antidepressants in the treatment of MDD.

Gregory Mattingly, MD, provides an overview of currently available treatment options for MDD.

Neither finasteride nor dutasteride were linked to an increased risk of suicide.